NCT04276415View on ClinicalTrials.gov

DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

March 11, 2022

Study Completion Date

March 11, 2022

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

DS-6157a

Administered as a single agent intravenously (IV) every 3 weeks

Trial Locations (5)

63110

Washington University of St. Louis, St Louis

77030

MD Anderson, Houston

97239

Oregon Health and Science University, Portland

02215

Dana Farber Cancer Institute, Boston

277-8577

National Cancer Center Hospital East, Tokyo

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY